Kura Oncology, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Kura Oncology, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-7.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 52% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 0/3Sales grew in 2 of the last 3 years; profit grew in 0 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-50.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 74% of Healthcare companies in United States.
Cash Cushion Ratio
+74%Cash, after subtracting all debt, equals 74% of its market value (net cash).
Higher than 84% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Kura Oncology, Inc. made a loss over the last year. Kura Oncology, Inc. owes $0.92 for every $1 it owns. Kura Oncology, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossKura Oncology, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
18.11The share price is 18.11 times Kura Oncology, Inc.'s book value per share, higher than 93% of Healthcare companies in United States.
Market cap
$877 MThe total market value of all of Kura Oncology, Inc.'s shares at today's price (share price × number of shares), larger than 62% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$48 MWhat Kura Oncology, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.54Net worth divided by the number of shares. The share price of $9.86 is 18.1 times this, which is the P/B above.
Return on equity (ROE)
-167.7%Kura Oncology, Inc. lost 167.7% of its shareholders' money over the last year, lower than 81% of Healthcare companies in United States.
Owes vs Owns
0.92×Kura Oncology, Inc. owes $0.92 for every $1 it owns (high), higher than 84% of Healthcare companies in United States.
Dividend yield
NoneKura Oncology, Inc. does not currently pay a dividend.
Revenue growth
+25%Revenue rose 25% in the year to Dec 2025.
Profit growth
LossKura Oncology, Inc. made a loss in each of the last two years.
Profit margin
-412.9%Kura Oncology, Inc. lost $413 for every $100 of revenue.
Interest cover
Not coveredKura Oncology, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashKura Oncology, Inc. held $647 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Kura Oncology, Inc.: $877 M ÷ $48 M (30 Jun 2026) = 18.1.
What is Kura Oncology, Inc.'s return on equity?
Kura Oncology, Inc. lost 167.7% of its shareholders' money over the last year, lower than 81% of Healthcare companies in United States.
How much does Kura Oncology, Inc. owe compared with what it owns?
Kura Oncology, Inc. owes $0.92 for every $1 it owns (high), higher than 84% of Healthcare companies in United States.
Does Kura Oncology, Inc. pay a dividend?
No. Kura Oncology, Inc. does not currently pay a dividend.
Is Kura Oncology, Inc.'s revenue growing?
Revenue rose 25% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.